PRPH ProPhase Labs Inc

ProPhase Labs to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 13, 2021 at 4:30 p.m. Eastern Time

ProPhase Labs to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 13, 2021 at 4:30 p.m. Eastern Time

GARDEN CITY, NY, April 15, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, will hold a conference call on Thursday, May 13, 2021 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2021. A press release detailing these results will be issued prior to the call.

ProPhase Labs’ CEO and Chairman of the Board of Directors, Ted Karkus, will host the conference call, followed by a question-and-answer period.

To access the call, please use the following information:

Date:Thursday, May 13, 2021
Time:4:30 p.m. Eastern time, 1:30 p.m. Pacific time
Toll-free dial-in number:1-877-407-0784
International dial-in number:1-201-689-8560
Conference ID:13718976

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact MZ Group at 1-949-491-8235.

The conference call will be broadcast live and available for replay at and via the investor relations section of the Company's website at .

A replay of the conference call will be available after 7:30 p.m. Eastern time through May 27, 2021.

Toll-free replay number:1-844-512-2921
International replay number:1-412-317-6671
Replay ID:13718976

About ProPhase Labs

ProPhase Labs (NASDAQ: PRPH) is a diversified medical science and technology company. The Company’s laboratory testing subsidiary, ProPhase Diagnostics, offers SARS-CoV-2 (COVID-19) and COVID-19 viral mutation PCR tests through both saliva and nasal swab methods at its CLIA certified laboratories. ProPhase Diagnostics also provides Respiratory Pathogen Panel (RPP) Molecular tests including Influenza A and B and others. Prophase Labs researches, develops, manufactures, distributes, markets and sells OTC consumer healthcare products and dietary supplements, including dietary supplements under the TK Supplements® brand. The Company actively pursues strategic investments and acquisition opportunities for other companies, technologies and products. For more information, visit .

Investor Contact

Chris Tyson

Managing Director

MZ Group - MZ North America

949-491-8235





EN
15/04/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ProPhase Labs Inc

 PRESS RELEASE

PROPHASE LABS, INC. ANNOUNCES COMPLETION OF IMPORTANT NEXT STEP FOR CR...

PROPHASE LABS, INC. ANNOUNCES COMPLETION OF IMPORTANT NEXT STEP FOR CROWN MEDICAL COLLECTIONS $50 MILLION A/R INITIATIVE COVID-19 TESTING LABORATORY SUBSIDIARIES FILE FOR BANKRUPCTY PROTECTION UNIONDALE, NY, Sept. 23, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics and consumer products company, announced that its three COVID-19 testing laboratory companies filed for reorganization under Chapter 11 in United States Bankruptcy Court for the District of New Jersey, advancing the Crown Medical Collections initiat...

 PRESS RELEASE

ProPhase Labs Stockholders Approve All Proposals at September 9, 2025 ...

ProPhase Labs Stockholders Approve All Proposals at September 9, 2025 Special Meeting By More Than 75% In Favor ProPhase Labs Stockholders Deliver Strong Mandate at Special Meeting UNIONDALE, NY, Sept. 12, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics and consumer products company, today announced that stockholders delivered a strong mandate at the Company’s September 9, 2025 Special Meeting, approving all proposals on the agenda. With each proposal receiving more than 75% support, ProPhase received clear au...

 PRESS RELEASE

ProPhase Labs Inc. to Participate in Renmark’s Virtual Non-Deal Roadsh...

ProPhase Labs Inc. to Participate in Renmark’s Virtual Non-Deal Roadshow Series on Thursday, September 4, 2025 Company cancels the Equity Line of Credit (ELOC) UNIONDALE, NY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, announced today that they will be participating in Renmark Financial Communications Inc’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Thursday, September 4, 2025, at 12:00 pm EDT. ProPhase Labs Inc. welcomes st...

 PRESS RELEASE

ProPhase Labs Announces Filing of Definitive Proxy Statement and New D...

ProPhase Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of Shareholders UNIONDALE, NY, Aug. 19, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, today announced that it filed a definitive proxy statement (“DEF 14A”) with the U.S. Securities and Exchange Commission (“SEC”) on Friday, August 15, 2025 and received a “no further comments” letter from the SEC’s Division of Corporation Finance Office of Life Sciences, indicating that the Staff had co...

 PRESS RELEASE

ProPhase Labs Announces Financial Results for the Three and Six Months...

ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025 ProPhase Delivers Significant Operational and Financial Improvements, Advances Multiple Non-Dilutive Liquidity Initiatives, and Targets Transformational Growth Catalysts Company granted key U.S. patent on BE-Smart™ Esophageal Adenocarcinoma Risk Assessment test (August 2025) Company to hold a virtual conference call Wednesday, August 13, 2025, at 2:00 PM ET UNIONDALE, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a diversified diagnostics,...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch